Ventoux Biosciences Launches Research Program Targeting Spinal Cord Injury with VEN-201
Ventoux Biosciences, a patient-founded biotechnology company developing therapies for immune-fibrotic diseases, today announced a research program that will explore the therapeutic potential of Ventoux's lead compound, VEN-201, in translational preclinical models of spinal cord injury (SCI). The research will be conducted by Dr. Michael Sofroniew, MD, PhD, Distinguished Professor of Neurobiology at the David Geffen […]